Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06596967 · ClinicalTrials.gov registry record · Phase 1

Heat Therapy in Type 2 Diabetes

A Phase 1 study of Type 2 Diabetes, sponsored by Purdue University.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT06596967: Recruiting Phase 1 study of Type 2 Diabetes, sponsored by Purdue University.

NCT06596967 is a Phase 1 study of Type 2 Diabetes that is actively recruiting participants, run by Purdue University. The registered enrollment target is 24 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06596967, a Phase 1 study of Type 2 Diabetes, is actively recruiting participants, sponsored by Purdue University.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This study aims to test whether home-based heat therapy (HT) can improve the health of older adults with type 2 diabetes (T2D). T2D is common in older adults and can lead to severe issues such as heart disease, disability, and early death. While regular exercise is known to help manage T2D, many people with the condition find it difficult to stay active. This study explores HT as a simple, non-invasive treatment that may offer similar benefits. Participants will wear special leg sleeves that deliver heat to their legs for 90 minutes each day at home over 12 weeks. The study\'s primary goal is to assess whether HT treatment at home is feasible and safe to use. We hypotesize that people with diabetes who receive heat therapy will have better blood sugar control, stronger legs, less body fat, and improved ability to walk, along with lower blood pressure. If successful, HT could offer a new option for people with T2D to manage their condition, especially for those who struggle with regular exercise. This research could lead to larger studies and help provide a practical way to improve health and quality of life for older adults with diabetes.

Primary Outcome

A built-in timer inside the pump that is inaccessible to participants will provide one assessment of patient compliance with the therapy. Compliance will be determined by dividing the number of hours of HT recorded use by the required hours. In addition, patients in both groups will receive a logbook to record their treatment sessions.

Conditions Studied

Interventions

  • DEVICE Sham
  • DEVICE Heat therapy

Study Locations (1)

Indiana

  • Purdue University - West Lafayette

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-09-03
Est. Completion 2025-07-31
Phase Phase 1
Purdue University

141 total trials

What NCT06596967 shows while recruiting

NCT06596967 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.

NCT06596967 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT06596967 about?

NCT06596967 is a clinical study titled "Heat Therapy in Type 2 Diabetes". This study aims to test whether home-based heat therapy (HT) can improve the health of older adults with type 2 diabetes (T2D). T2D is common in older adults and can lead to severe issues such as heart disease, disability, and early death. While regular exercise is known to help manage T2D, many peo...

What is the current status of trial NCT06596967?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-09-03. Estimated completion is 2025-07-31.

What conditions does trial NCT06596967 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT06596967?

The interventions under investigation include: Sham (DEVICE), Heat therapy (DEVICE).

Who is sponsoring clinical trial NCT06596967?

This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06596967 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06596967's enrollment target sits among peer trials

24 279th of 327 higher than 45 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06596967, the US trial registry maintained by the National Library of Medicine. NCT06596967 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.